The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2

The efficacy of aprotinin combinations with selected antiviral-drugs treatment of influenza virus and coronavirus (SARS-CoV-2) infection was studied in mice models of influenza pneumonia and COVID-19. The high efficacy of the combinations in reducing virus titer in lungs and body weight loss and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivashchenko, Andrey A., Zagribelnyy, Bogdan A., Ivanenkov, Yan A., Ivashchenko, Ilya A., Karapetian, Ruben N., Kravchenko, Dmitry V., Savchuk, Nikolay P., Yakubova, Elena V., Ivachtchenko, Alexandre V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370800/
https://www.ncbi.nlm.nih.gov/pubmed/35956925
http://dx.doi.org/10.3390/molecules27154975
Descripción
Sumario:The efficacy of aprotinin combinations with selected antiviral-drugs treatment of influenza virus and coronavirus (SARS-CoV-2) infection was studied in mice models of influenza pneumonia and COVID-19. The high efficacy of the combinations in reducing virus titer in lungs and body weight loss and in increasing the survival rate were demonstrated. This preclinical study can be considered a confirmatory step before introducing the combinations into clinical assessment.

Ejemplares similares